Announcement on Convening the Q3 2024 Performance Briefing
Filed with SSE · · 3 pages · Chinese
Earlier from InnoCare Pharma
- Announcement on Voluntary Disclosure of Phase II Clinical Trial Result of ICP-488
- Announcement on the Resignation of Non-executive Directors and Independent Non-executive Directors and the Change of Members of Special Committees of the Board of Directors
- Announcement on Change of Sponsor Representative for Continuous Supervision
- Announcement on Listing and Circulation of Initial Public Offering of Strategic Placement Restricted Shares
- Announcement on Voluntary Disclosure of Clinical Trial Progress of Aobrutinib
Later from InnoCare Pharma
- The Q3 2024 Report
- Summary Announcement on the 2024 STAR Market Restricted Stock Incentive Plan (Draft)
- Notice on Convening the 1st Extraordinary General Meeting (Shareholders' Special Meeting) in 2024
- Notice on the Review Opinions and Remarks on Publicity of Lis of Incentive Recipients List for the Initial Grant of the 2024 SSE STAR Market Restricted Stock Incentive Plan
- Announcement on the First Granting of Restricted Stocks to Incentive Objects
Follow InnoCare Pharma into a list and get an email when it puts out news.
Follow InnoCare Pharma